DK2959916T3 - Ny europæisk PRRSV-stamme. - Google Patents

Ny europæisk PRRSV-stamme. Download PDF

Info

Publication number
DK2959916T3
DK2959916T3 DK15174330.9T DK15174330T DK2959916T3 DK 2959916 T3 DK2959916 T3 DK 2959916T3 DK 15174330 T DK15174330 T DK 15174330T DK 2959916 T3 DK2959916 T3 DK 2959916T3
Authority
DK
Denmark
Prior art keywords
challenge
prrs
group
seq
prrsv
Prior art date
Application number
DK15174330.9T
Other languages
English (en)
Inventor
Stefan Pesch
Kim Burgard
Volker Ohlinger
Francois-Xavier Orveillon
Jeremy Kroll
Sarah Layton
Michael Dennis Piontkowski
Michael B Roof
Philip Utley
Eric Martin Vaughn
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Application granted granted Critical
Publication of DK2959916T3 publication Critical patent/DK2959916T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (18)

1. Sammensætning omfattende porcin reproduktions- og respiratorisk syndrom-virus (PRRSV) af en europæisk type, som er af stammen deponeret hos European Collection of Cell Cultures (ECACC) under deponeringsnummeret ECACC 11012502.
2. Sammensætning ifølge krav 1, hvor nævnte PRRSV er svækket ved passage mindst 36 gange i cellekultur, således at den modificerede virus, når den indgives til et svin eller andet pattedyr udsat for PRRSV, ikke forårsager kliniske tegn på PRRSV-sygdom, men er i stand til at fremkalde en immunreaktion, som immuniserer dyret mod patogene former af PRRSV.
3. Sammensætning ifølge krav 1 eller 2, som er på frysetørret form.
4. Sammensætning ifølge et hvilket som helst af kravene 1 til 3, hvor sammensætningen formuleres til at tillade indgift af 101 til 107 viruspartikler per dosis, eller hvor sammensætningen omfatter mindst cirka 107 viruspartikler.
5. Sammensætningen ifølge et hvilket som helst af kravene 1 til 4, som yderligere omfatter et eller flere svækkede eller inaktiverede patogener, som ikke er PRRSV, eller antigent materiale deraf.
6. Sammensætning ifølge krav 5, hvor patogenerne, der ikke er PRRSV, er udvalgt blandt pseudorabies-virus, svineinfluenzavirus, svineparvovirus, overførbar gastroenteritisvirus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cho-lerasuis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae og Actinobacillus pleuropneumoniae.
7. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, yderligere omfattende en adjuvans, eventuelt udvalgt fra gruppen bestående af MCP-1, α-tokoferol (f.eks. a-tokoferolacetat), Haemophilus sonmus-fraktioner, carbopol og kombinationer deraf.
8. Sammensætning ifølge et hvilket som helst af kravene 1 til 7 til anvendelse som en vaccine.
9. Sammensætning ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i en fremgangsmåde til - at behandle eller mildne sværhedsgraden af infektion med porcin reproduktions- og respiratorisk syndrom-virus (PRRSV), - at forebygge PRRSV-infektion, - at fremkalde dannelsen af en antistofreaktion mod PRRS-virus, og/eller - at mindske sværhedsgraden af et eller flere kliniske symptomer forbundet med PRRSV-infektion, hvor det ene eller de flere kliniske symptomer fortrinsvis er udvalgt fra gruppen bestående af lungelæsioner, anoreksi, hudmisfarvninger, letargi, åndedrætssymptomer, mumificerede smågrise, hoste, diarré og kombinationer deraf.
10. Sammensætning ifølge krav 7 til anvendelse i en fremgangsmåde til - at nedbringe procentdelen af lungelæsioner med mindst 50 % sammenlignet med dyr, der ikke modtager den immunogene sammensætning i kombination med ad-juvansen, - at nedbringe viræmi hos dyrene med mindst 45 % sammenlignet med dyr, der ikke modtager den immunogene sammensætning i kombination med adjuvansen.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 8 til 10, hvor fremgangsmåden indbefatter trinnet at indgive en terapeutisk mængde af et PRRSV-antigen til - en smågris cirka tre uger gammel eller yngre, - et svin mellem cirka 3 og 4 uger gammelt, - et svin mellem cirka fire og seksten uger gammelt, hvor svinet eventuelt er mellem fem og seks uger gammelt eller ni til femten uger gammelt eller syv til ti uger gammelt, eller - et svin, der er ældre end seksten uger, hvor svinet ældre end seksten uger eventuelt er en gylt eller en voksen so.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 8 til 11, hvor sammensætningen skal indgives - i en dosis på 1 ml for svin og 2 ml for søer via intramuskulær injektion, og/eller - i en enkelt dosis.
13. Vaccineprodukt omfattende i særskilte beholdere en frysetørret sammensætning ifølge et hvilket som helst af kravene 1 til 7 og et opløsningsmiddel til rekonstituering, og eventuelt ydermere indeholdende en indlægsseddel eller etiket omfattende brugsanvisning.
14. Vaccineprodukt ifølge krav 13, hvor - opløsningsmidlet er udvalgt fra gruppen bestående af vand, fysiologisk saltopløsning eller buffer eller en adjuverende opløsning, og/eller - opløsningsmidlet indeholder en adjuvans.
15. Proteinsammensætning omfattende - et protein med sekvensen ifølge SEQ ID NO:7, eller - proteinerne med sekvenserne ifølge SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 og SEQ ID NO:9.
16. Isoleret nukleinsyre omfattende - sekvensen ifølge SEQ ID NO:24, eller - sekvenserne ifølge SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25 og SEQ ID NO:26.
17. Rekombinant ekspressionsvektor omfattende en nukleinsyresekvens, der koder for (i) den åbne læseramme i PRRSV ifølge SEQ ID NO:7, virkningsmæssigt forbundet til en promotor, eller (ii) de åbne læserammer i PRRSV ifølge SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 og SEQ ID NO:9, virkningsmæssigt forbundet til en promotor.
18. Rekombinant ekspressionsvektor ifølge krav 17, hvor (i) nukleinsyresekvensen, der koder for den åbne læseramme, er SEQ ID NO:24, eller (ii) nukleinsyresekvensen, der koder for de åbne læserammer, omfatter SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25 og SEQ ID NO:26.
DK15174330.9T 2011-02-17 2012-02-14 Ny europæisk PRRSV-stamme. DK2959916T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161444074P 2011-02-17 2011-02-17
EP12704409.7A EP2675475B1 (en) 2011-02-17 2012-02-14 Novel european prrsv strain

Publications (1)

Publication Number Publication Date
DK2959916T3 true DK2959916T3 (da) 2018-10-29

Family

ID=45614840

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12704409.7T DK2675475T3 (da) 2011-02-17 2012-02-14 Ny europæisk prrsv-stamme
DK15174330.9T DK2959916T3 (da) 2011-02-17 2012-02-14 Ny europæisk PRRSV-stamme.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12704409.7T DK2675475T3 (da) 2011-02-17 2012-02-14 Ny europæisk prrsv-stamme

Country Status (30)

Country Link
US (4) US8765142B2 (da)
EP (2) EP2959916B1 (da)
JP (1) JP5788027B2 (da)
KR (2) KR102073075B1 (da)
CN (2) CN106110318A (da)
AR (2) AR085272A1 (da)
AU (2) AU2012217169B2 (da)
BR (2) BR122021013826B1 (da)
CA (1) CA2826341C (da)
CL (1) CL2013002379A1 (da)
CO (1) CO6791570A2 (da)
CY (1) CY1116835T1 (da)
DK (2) DK2675475T3 (da)
EA (2) EA035624B1 (da)
ES (2) ES2550258T3 (da)
HR (1) HRP20151031T1 (da)
HU (1) HUE027731T2 (da)
ME (1) ME02271B (da)
MX (2) MX345188B (da)
MY (2) MY186535A (da)
PH (1) PH12017500962A1 (da)
PL (2) PL2675475T3 (da)
PT (2) PT2675475E (da)
RS (1) RS54231B1 (da)
SG (1) SG192820A1 (da)
SI (1) SI2675475T1 (da)
SM (1) SMT201500236B (da)
TW (2) TWI665303B (da)
UA (2) UA112768C2 (da)
WO (1) WO2012110489A2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110490A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
MY186535A (en) 2011-02-17 2021-07-26 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
US8906385B2 (en) 2011-12-01 2014-12-09 University Of Maryland, College Park Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
KR102012109B1 (ko) * 2012-05-17 2019-08-19 조에티스 엘엘씨 이유 전 돼지 생식기 호흡기 증후군(prrs) 바이러스에 대한 효과적인 백신접종
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9457073B2 (en) * 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
MX366051B (es) 2012-12-07 2019-06-26 Univ Illinois Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
DK3083947T3 (da) * 2013-12-20 2019-07-08 Boehringer Ingelheim Vetmedica Gmbh Prrs-virusvariant, cdna-klon af europæisk prrs-virus, samt anvendelser deraf
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
ES2743223T3 (es) * 2014-10-27 2020-02-18 Pharmacosmos Holding As Tratamiento o prevención de la anemia en mamíferos no humanos gestantes y crías
CN106924726B (zh) * 2015-12-29 2021-02-09 普莱柯生物工程股份有限公司 一种用于预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用
CA3022006A1 (en) * 2016-05-11 2017-11-16 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
CA3042584A1 (en) 2016-11-03 2018-05-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
EP3554537A2 (en) 2016-12-14 2019-10-23 Zoetis Services LLC Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
US11013796B2 (en) 2018-08-30 2021-05-25 Iowa State University Research Foundation, Inc. Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom
EP3953370A1 (en) 2019-04-04 2022-02-16 Boehringer Ingelheim Animal Health USA Inc. Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
CN110735005B (zh) * 2019-11-26 2023-01-10 广西大学 Siv和prrsv多重rt-pcr快速检测试剂盒及引物
CN111676247A (zh) * 2020-06-30 2020-09-18 扬州大学 一株猪繁殖与呼吸综合征病毒1型分离株感染性克隆构建、拯救与应用
MX2023001024A (es) 2020-07-24 2023-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina combinada.
CN113862230B (zh) * 2021-09-30 2023-08-08 中牧实业股份有限公司 一种猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE148705C (da)
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3080291A (en) 1960-06-10 1963-03-05 Jensen Salsberg Lab Inc Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4015100A (en) 1974-01-07 1977-03-29 Avco Everett Research Laboratory, Inc. Surface modification
US4122167A (en) 1977-02-09 1978-10-24 Merck & Co., Inc. Respiratory synctial vaccine
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4224412A (en) 1979-05-01 1980-09-23 Dorofeev Viktor M Living virus culture vaccine against canine distemper and method of preparing same
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
GB8319302D0 (en) 1983-07-16 1983-08-17 Tpt Ltd Container
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3405100A1 (de) 1984-02-14 1985-08-14 Drägerwerk AG, 2400 Lübeck Pt-katalysator auf einem traeger als luftreinigungsmittel
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5206163A (en) 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
DE3687769T2 (de) 1985-07-08 1993-09-02 Chiron Corp Vakzine und diagnostika, die vom bovine-diarrhea-virus stammen.
US4753884A (en) 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
JPS62198626A (ja) 1986-02-26 1987-09-02 Biseibutsu Kagaku Kenkyusho:Kk 血球凝集性脳脊髄炎ウイルス感染症予防ワクチン
FR2602791B1 (fr) 1986-08-18 1988-11-10 Ministere Agri Direction Quali Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
NZ222465A (en) 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
DE3833925A1 (de) 1988-03-11 1989-09-21 Inst Angewandte Biotechnologie Verfahren und herstellung von virus und viralem antigen und vorrichtung hierzu
US5213759A (en) 1988-05-05 1993-05-25 Elopak Systems A.G. Sterilization
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
EP0587780B2 (en) 1991-06-06 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
WO1993003760A1 (en) 1991-08-26 1993-03-04 James Edward Collins Sirs vaccine and diagnosis method
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
CA2076744C (en) 1991-08-26 2000-06-27 Danny W. Chladek Viral agent associated with mystery swine disease
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
US6080570A (en) 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
JPH07501049A (ja) 1991-10-14 1995-02-02 アクゾ・ノベル・エヌ・ベー ブタ生殖・呼吸系症候群ワクチン及び診断方法
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
TW289731B (da) 1992-07-09 1996-11-01 Akzo Nv
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5419907A (en) 1992-11-10 1995-05-30 Iowa State University Research Foundation, Inc. Pathogenic porcine respiratory coronavirus
ES2152304T3 (es) 1993-02-08 2001-02-01 Bayer Ag Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas.
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP0659885A1 (en) 1993-12-21 1995-06-28 Akzo Nobel N.V. Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity
DE4407489A1 (de) 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
ES2165405T3 (es) 1994-04-11 2002-03-16 Akzo Nobel Nv Cepas de vacuna europeas del virus del sindrome reproductor y respiratorio porcino (prrsv).
DE69530227T2 (de) 1994-04-15 2004-04-01 Temple University Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
DE69535061T2 (de) 1994-08-05 2007-01-25 Regents Of The University Of Minnesota, Minneapolis Virale nukleotidsequenz vr-2332 und nutzungsverfahren
PT732340E (pt) 1995-03-14 2004-09-30 Akzo Nobel Nv Expressao de polipeptidos do virus da sindrome reprodutiva e respiratoria porcina na mesma celula
US5690940A (en) 1995-06-21 1997-11-25 Regents Of The University Of Minnesota Low pathogencity PRRS live virus vaccines and methods of preparation thereof
ES2102971B1 (es) 1996-01-25 1998-03-01 Hipra Lab Sa Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
SK119498A3 (en) 1996-03-01 1999-07-12 Schering Corp Porcine reproductive and respiratory syndrome vaccine
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6015663A (en) 1996-03-01 2000-01-18 The United States Of America As Represented By The Secretary Of Agriculture Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains
US5976537A (en) 1996-07-02 1999-11-02 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
WO2000053787A1 (en) 1999-03-08 2000-09-14 Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V. Prrsv vaccines
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
WO1998035023A1 (en) * 1997-02-07 1998-08-13 Origen, Inc. Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
AU754938B2 (en) 1997-05-06 2002-11-28 Boehringer Ingelheim Vetmedica Gmbh PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays
IN1998CH01219A (en) 1997-06-04 2005-03-04 Calgene Llc Production of polyunsaturated fatty acid by expression of polyketide-like synthesis genes in plants
WO1998055626A2 (en) 1997-06-05 1998-12-10 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
DK1183332T3 (da) 1999-04-22 2010-09-06 Us Agriculture Porcint Reproduktions- og Respirations Syndrom-vaccine baseret på isolere JA-142
WO2002095040A1 (en) 2001-05-21 2002-11-28 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Delections in arterivirus replicons
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
US20020012670A1 (en) 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
DE60121545T2 (de) * 2000-02-08 2007-06-28 Regents Of The University Of Minnesota, Minneapolis Virus des porcinen reproduktiven und respiratorischen syndroms und dessen verwendung
EP1156111A1 (en) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimeric arterivirus-like particles
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
CZ20032743A3 (cs) * 2001-03-09 2004-02-18 Boehringer Ingelheim Vetmedica Gmbh Atenuované kmeny viru PRRS
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
EP1350840B1 (en) 2002-04-05 2012-05-09 Boehringer Ingelheim Vetmedica GmbH Adaptation sites of PRRSV
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7722878B2 (en) 2004-06-17 2010-05-25 Boehringer Ingelheim Vetmedica, Inc. PRRSV subunit vaccines
BRPI0510928A (pt) 2004-06-18 2007-11-13 Univ Minnesota identificação de organismos viralmente infectados e vacinados
CN101039693A (zh) * 2004-06-18 2007-09-19 明尼苏达大学董事会 鉴定病毒感染和疫苗接种的生物
US20060063151A1 (en) 2004-09-21 2006-03-23 Michael Roof Porcine reproductive and respiratory syndrome isolates and methods of use
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
RU2007117510A (ru) * 2004-11-11 2008-11-20 Пфайзер Продактс Инк. (Us) Мутантный вирус репродуктивного и респираторного синдрома свиней
DK1833508T3 (da) * 2004-11-19 2010-12-06 Intervet Int Bv Virusstammer og sammensætninger af PRRS-syndromet (porcint reproduktivt og respiratorisk syndrom)
ATE462445T1 (de) 2005-01-13 2010-04-15 Boehringer Ingelheim Vetmed Prrs-impfstoffe
UA95778C2 (ru) 2005-06-24 2011-09-12 Риджентс Оф Зе Юниверсити Оф Миннесота Вирусы репродуктивно-респираторного синдрома свиней, их инфекционные клоны и мутанты и способы применения
EP1962900A2 (en) 2005-11-29 2008-09-03 Iowa State University Research Foundation, Inc. Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof
WO2008109237A2 (en) * 2007-02-13 2008-09-12 Washington State University Research Foundation Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
WO2008121958A1 (en) 2007-04-02 2008-10-09 Boehringer Ingelheim Vetmedica, Inc. Use of prrsv vaccines to reduce pcv2 viremia
US20100003278A1 (en) 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
UA106475C2 (uk) 2008-08-25 2014-09-10 Берингер Ингельхайм Ветмедика, Инк. Спосіб вакцинації свині проти високопатогенного репродуктивно-респіраторного синдрому свиней (hp prrs)
US20100129398A1 (en) 2008-11-26 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome
ES2742262T3 (es) 2010-04-16 2020-02-13 Univ Gent Vacuna con protección cruzada para el virus del síndrome respiratorio y reproductivo porcino
CN101920010A (zh) * 2010-06-29 2010-12-22 西北农林科技大学 表达prrsv免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
US8728487B2 (en) 2011-01-20 2014-05-20 Hua Wu Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome
MY186535A (en) 2011-02-17 2021-07-26 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
WO2012110490A1 (en) * 2011-02-17 2012-08-23 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
EP2968513A2 (en) 2013-03-15 2016-01-20 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
DK3083947T3 (da) 2013-12-20 2019-07-08 Boehringer Ingelheim Vetmedica Gmbh Prrs-virusvariant, cdna-klon af europæisk prrs-virus, samt anvendelser deraf

Also Published As

Publication number Publication date
EA201300915A1 (ru) 2014-02-28
JP5788027B2 (ja) 2015-09-30
PL2959916T3 (pl) 2019-05-31
TW201638333A (zh) 2016-11-01
US8765142B2 (en) 2014-07-01
AU2012217169B2 (en) 2016-08-11
WO2012110489A2 (en) 2012-08-23
ES2550258T3 (es) 2015-11-05
KR102073075B1 (ko) 2020-02-26
WO2012110489A3 (en) 2012-10-11
KR20140006040A (ko) 2014-01-15
AU2016204983A1 (en) 2016-08-04
EP2675475A2 (en) 2013-12-25
EA201692359A1 (ru) 2017-04-28
EA035624B1 (ru) 2020-07-16
ME02271B (me) 2016-02-20
PH12017500962A1 (en) 2017-11-20
EP2959916A1 (en) 2015-12-30
US10668144B2 (en) 2020-06-02
CO6791570A2 (es) 2013-11-14
ES2692809T3 (es) 2018-12-05
MX2013009485A (es) 2014-07-09
US20140255442A1 (en) 2014-09-11
JP2014507151A (ja) 2014-03-27
AU2016204983B2 (en) 2018-02-15
US20120213810A1 (en) 2012-08-23
CN106110318A (zh) 2016-11-16
BR122021013826B1 (pt) 2022-11-22
BR112013021076A2 (pt) 2020-12-15
TWI665303B (zh) 2019-07-11
SI2675475T1 (sl) 2015-10-30
CA2826341C (en) 2022-02-22
CN103370078A (zh) 2013-10-23
CA2826341A1 (en) 2012-08-23
KR102183276B1 (ko) 2020-11-26
UA117272C2 (uk) 2018-07-10
AU2012217169A1 (en) 2013-07-18
SG192820A1 (en) 2013-09-30
US9534207B2 (en) 2017-01-03
HUE027731T2 (en) 2016-10-28
US20170065709A1 (en) 2017-03-09
EP2675475B1 (en) 2015-07-01
RS54231B1 (en) 2015-12-31
KR20200015800A (ko) 2020-02-12
US10039821B2 (en) 2018-08-07
MY161198A (en) 2017-04-14
BR112013021076B1 (pt) 2022-11-29
AR117530A2 (es) 2021-08-11
DK2675475T3 (da) 2015-09-14
MX345188B (es) 2017-01-20
TW201300538A (zh) 2013-01-01
US20190134180A1 (en) 2019-05-09
EP2959916B1 (en) 2018-08-08
PT2675475E (pt) 2015-10-22
TWI673362B (zh) 2019-10-01
PL2675475T3 (pl) 2015-12-31
MX355058B (es) 2018-04-04
PT2959916T (pt) 2018-11-19
HRP20151031T1 (hr) 2015-11-06
UA112768C2 (uk) 2016-10-25
EA038012B1 (ru) 2021-06-23
MY186535A (en) 2021-07-26
SMT201500236B (it) 2015-10-30
CY1116835T1 (el) 2017-03-15
AR085272A1 (es) 2013-09-18
CL2013002379A1 (es) 2014-02-14
CN103370078B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
US10668144B2 (en) European PRRSV strain
US7368117B2 (en) PRRS vaccines
EP0595436A2 (en) Porcine respiratory and reproductive disease virus, vaccines and viral DNA
US10155035B2 (en) Porcine reproductive and respiratory syndrome vaccine virus